FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention concerns a product with antioxidant, virucidal, immunostimulating, antihypoxic and antiplatelet effects. The following is disclosed: the use of 2-ethyl-6-methyl-3-hydroxypyridinium-gammalactone-2,3-dehydro-L-gulonoate (ascorbate) of formula (I) for the treatment of influenza, coronavirus infection COVID-19, as well as their complications associated with the development of thrombosis.
(I)
EFFECT: use of the invention makes it possible to have a complex effect on different pathophysiological pathways of development of influenza, coronavirus infection COVID-19 during their treatment, as well as influence their complications associated with the development of thrombosis.
1 cl, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATION FOR COMPLEX THERAPY OF DISEASES CAUSED BY BETA-CORONAVIRUSES | 2020 |
|
RU2739212C1 |
| AN ANTIVIRAL AGENT AGAINST SARS-COV-2 CORONAVIRUS | 2022 |
|
RU2788762C1 |
| MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| METHOD FOR DETECTING ANTIBODIES - CLASS G IMMUNOGLOBULINS IN BLOOD SERUM TO PATHOGENS OF SEVERE ACUTE RESPIRATORY VIRAL INFECTIONS, INCLUDING SARS-COV-2, WITH SIMULTANEOUS PROGNOSIS OF COVID-19 SEVERITY, BASED ON HYDROGEL BIOCHIP | 2020 |
|
RU2746815C1 |
| METHOD FOR CORONAVIRUS INFECTION TREATMENT | 2021 |
|
RU2751488C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES | 2021 |
|
RU2780252C1 |
| METHOD FOR TREATING DYSOSMIA CAUSED BY CORONAVIRUS INFECTION | 2021 |
|
RU2791808C2 |
| INTERFERON INDUCTOR "FLORENTA" AND A METHOD FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2783947C1 |
